Avalo Therapeutics, Inc.

NASDAQ:AVTX

Biotechnology

Healthcare
$6.70 -2.18%

-$0.34 today

Market cap
$387.41M
Beta
0.82
P/E (TTM)
-3.6
EPS (TTM)
-$4.21
52W Low $4.50High $24.27

Volume 1.58M

Average 1.61M

AVTX Operating Cash Flow

Cash generated by the company's core business operations during the period.

Avalo Therapeutics, Inc.NASDAQ: AVTX

Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Operating cash flow growth accelerates

Q1 FY2026 operating cash flow of $17.69M (cash outflow) rose 87.1% year over year, ahead of the +14.1% change in trailing-twelve-month operating cash flow. Sequentially, it rose 24.2% from the prior quarter. Over 3 fiscal years it compounded at +24.4% a year.

Context

  • Operating cash flow amounted to 87216.9% of revenue in FY2025, up 76093.1 pp from a year earlier.
  • Operating cash flow grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +87.1% holds above the trailing-twelve-month pace of +14.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$17.69M+24.2% QoQ
Last fiscal yearDec 2025
-$51.46M+4.9% YoY
LTMMar 2026
-$59.69M+14.1% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+87.1%——
1 year+4.9%——
3-year CAGR+24.4%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
(51.46M) USD
Year-over-year change
-4.9%

Operating Cash Flow vs competitors

How AVTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +14.1% is the 6th highest of 9, against a peer median of +39.8%.
  • Operating cash flow amounts to 101172.9% of revenue for AVTX, versus a peer median of 235.8%.
AVTX Competitors
Operating Cash Flow for AVTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYRESpyre Therapeutics, Inc.LTM Sep 2026$249.32M USD+54.0%+28.3%275.5%
XNCRXencor, Inc.LTM Jun 2026$205.81M USD+53.4%—196.1%
IMUXImmunic, Inc.LTM Mar 2026$81.33M USD-1.5%+9.6%—
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$68.89M USD+26.2%+29.9%—
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$59.69M USD+14.1%+24.4%101172.9%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$52.21M USD+323.8%-11.3%623.9%
IFRXInflaRx N.V.LTM Mar 2026€28.81M EUR-39.6%+0.2%98232.5%
QTTBQ32 Bio Inc.LTM Mar 2026$27.4M USD-58.3%+45.2%51.0%
ANABAnaptysBio, Inc.LTM Mar 2026$4.48M USD+104.1%—1.9%
ODTXOdyssey Therapeutics, Inc.—— ———
AGMBAgomAb Therapeutics N.V. American Depositary Shares—— ———
Peer median (excluding AVTX) —+39.8%+19.0%235.8%

Competitors are the stored peer set for AVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(84.38M)(41.66M)(31.54M)(35.13M)(78.26M)
Depreciation & Amortization1.66M166K158K169K344K
Deferred Income Tax22K28K14K114K165K
Stock-Based Compensation8.17M7.55M3.48M5.85M13.62M
Change in Working Capital2.84M(60K)(9.24M)(4.71M)3.84M
Accounts Receivables1.12M2.88M1.78M(475K)0
Inventory(35K)18K20K00
Accounts Payables796K(487K)(2.44M)(163K)(146K)
Other Working Capital961K(2.47M)(8.61M)(4.07M)3.99M
Other Non-Cash Items794K7.22M6.46M(15.35M)8.83M
Operating Cash Flow(70.89M)(26.75M)(30.68M)(49.06M)(51.46M)
Capital Expenditures(113K)(95K)(158K)00
Acquisitions (Net)000356K0
Purchases of Investments0000(113.72M)
Sales of Investments000031.31M
Other Investing Activities0025K0690K
Investing Cash Flow(113K)(95K)(133K)356K(81.72M)
Debt Repayment32.9M(14.81M)(21.24M)00
Common Stock Issued71.93M107K46.22M115.63M15.1M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.93M067K60.22M(510K)
Financing Cash Flow106.76M(14.7M)25.04M175.85M14.59M
Effect of Forex Changes096K000
Net Change in Cash35.76M(41.45M)(5.77M)127.15M(118.59M)
Free Cash Flow(71.01M)(26.85M)(30.84M)(49.06M)(51.46M)

Avalo Therapeutics, Inc.

NASDAQ:AVTX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.